Table 2.
Independent risk factors for FN in solid tumors (risk score model studies).
| Reference | Study Population | Risk Factors (Multivariate Analysis) |
|---|---|---|
| Aagaard et al. (2018) [57] |
Patients with solid tumors and DLBCL treated with first-line chemotherapy (n = 9458) | Female sex, age > 65 years, cancer type, disease stage, low albumin, elevated bilirubin, low estimated glomerular filtration rate, infection before baseline, treatment with more than one chemotherapy drug (two to four), receiving taxane-based chemotherapy |
| Aagaard et al. (2020) [59] |
Patients with solid tumors who initiated cycle 2 of standard first-line chemotherapy (n = 6885) |
Higher predicted risk for FN in the first cycle, platinum- and taxane-containing regimens, concurrent radiotherapy, treatment in cycle 2 compared to later cycles, previous FN or neutropenia, not receiving G-CSF |
| Hosmer et al. (2011) [55] |
Elderly patients with breast, lung, colorectal, and prostate cancer (n = 58,053) |
Advanced age at diagnosis, number of associated comorbid conditions, receipt of immunosuppressive chemotherapy, receipt of chemotherapy within one month of diagnosis |
| Lyman et al. (2011) [56] * |
Patients with breast, lung, colorectal, ovarian cancer, and lymphoma patients (n = 4458) | Prior chemotherapy, use of other immunosuppressive medications, abnormal hepatic and renal function, low white blood count, chemotherapy and planned delivery ≥ 85%, small cell lung cancer, specific classes of chemotherapy (anthracyclines, taxanes, certain alkylating agents [cyclophosphamide, ifosfamide], class I/II topoisomerase inhibitors, platinum derivates [cisplatin, carboplatin], gemcitabine, vinorelbine) |
| Razzaghdoust et al. (2018) [58] * |
Patients with various solid tumors and lymphomas (n = 305) | High-risk chemotherapy regimen without G-CSF, intermediate-risk regimen without G-CSF, age > 65 years, elevated ferritin, BMI < 1.73 kg/m2, BSA < 2 m2, estimated glomerular filtration rate < 60 mL/min/1.73 m2, elevated C-reactive protein |
* prospectively validated studies, DLBCL–Diffuse large B-cell lymphoma, FN–febrile neutropenia, G-CSF–Granulocyte colony-stimulating factors, BMI–body mass index, BSA–body surface area.